# A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

> **NCT04987489** · PHASE2 · COMPLETED · sponsor: **Forma Therapeutics, Inc.** · enrollment: 53 (actual)

## Conditions studied

- Sickle Cell Disease
- Thalassemia

## Interventions

- **DRUG:** Etavopivat tablets

## Key facts

- **NCT ID:** NCT04987489
- **Lead sponsor:** Forma Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-28
- **Primary completion:** 2025-09-03
- **Final completion:** 2025-09-24
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04987489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04987489, "A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04987489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*